State Street Holds 4.3% Of Altimmune Without Seeking To Influence Its Control

The September 30 position came into view Tuesday, while Altimmune plans a December FDA meeting on its alcohol-use-disorder program.

Share
State Street Holds 4.3% Of Altimmune Without Seeking To Influence Its Control

State Street reported a 4.3% passive stake in Altimmune, which develops treatments for serious liver diseases, in an SEC ownership filing Tuesday. The position dates to September 30, rather than to Monday's announcement of positive results for the company's experimental drug pemvidutide in alcohol use disorder.

8.4 Million Shares, Passive Ownership

State Street's reported position covered 8,356,408 common shares. It had shared voting authority over 8,164,809 shares and shared authority to dispose of 8,356,408 shares.

State Street certified that the securities were obtained and held as part of its ordinary business, without a purpose or effect of changing or influencing Altimmune's control. The 4.3% figure measures beneficial ownership of the common-stock class.

Pemvidutide's Heavy-Drinking Results

Altimmune said Monday that its mid-stage RECLAIM study in adults with moderate-to-severe alcohol use disorder met its main goal. At 24 weeks, pemvidutide recipients recorded a 4.20-day reduction in heavy drinking days per week, versus a 2.75-day reduction in the placebo group.

The company also said 42.2% of participants given pemvidutide reached zero heavy drinking days, compared with 17.4% given placebo.

Naim Alkhouri, chief medical officer of Summit Clinical Research, said no approved therapies currently address the interconnected health consequences of alcohol use disorder and alcohol-associated liver disease.

A Drug Developer Without Approved Products

Pemvidutide is Altimmune's lead drug candidate, a weekly peptide injection that activates glucagon and GLP-1 receptors. The company is testing it for metabolic dysfunction-associated steatohepatitis, or MASH, as well as alcohol use disorder and alcohol-associated liver disease.

Altimmune has no products approved for sale; its business depends on its candidates advancing through trials and regulatory review. As of December 31, 2025, more than 700 patients had received pemvidutide across eight completed studies and two ongoing studies.

The FDA has granted the candidate Breakthrough Therapy and Fast Track designations for MASH, and Fast Track designation for alcohol use disorder. Altimmune's market value was $412 million as of 6:44 a.m. ET Tuesday.

Altimmune is scheduled to meet with the FDA in December to discuss how to design a late-stage trial program for alcohol use disorder.

Sources

More on Altimmune

All Altimmune (ALT) coverage →